Real world treatment data of secondary central nervous system involvement in patients with large B-cell lymphoma, a multicenter retrospective Study in Japan (CONSENSUS)

Real world treatment data of secondary central nervous system involvement in patients with large B-cell lymphoma, a multicenter retrospective Study in Japan (CONSENSUS) - Real world treatment data of secondary central nervous system involvement in patients with large B-cell lymphoma, a multicenter retrospective Study in Japan (CONSENSUS)

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000054850

Enrollment

520

Registered

2024-07-08

Start date

2024-07-08

Completion date

Unknown

Last updated

2026-09-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Large B-cell lymphoma with secondary nervous system involvement

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients who meet all the following criteria are eligible. 1.Patients who were histologically diagnosed with large B-cell lymphoma between January 1, 2012 and December 31, 2022. 2.Patients who have involvement of the central nervous system at either newly diagnosed or relapse.

Exclusion criteria

Exclusion criteria: Patients with one or more of the following are excluded. 1.Patients who were diagnosed primary DLBCL of the central nervous system. 2.Patients who were treated with chemotherapy or radiotherapy for previously diagnosed lymphomas other than large B-cell lymphoma. 3.Patients who refused to consent to participate this research. 4.Patients with HIV antibody positive (not excluded if HIV antibody not measured).

Design outcomes

Primary

Measure	Time frame
Overall survival of diffuse large B-cell lymphoma patients with secondary nervous system involvement diagnosed between 2012 and 2022 at participating institutes.	—

Secondary

Measure	Time frame
Clinical features, treatment and risk factors affecting relapse and survival in diffuse large B-cell lymphoma patients with secondary nervous system involvement diagnosed between 2012 and 2022 at participating institutes.	—

Countries

Japan

Contacts

Public ContactHirokazu Sasaki

Nagoya City University Graduate School of Medical Sciences Department of Hematology & Oncology

hsasaki@med.nagoya-cu.ac.jp052-853-8738

Outcome results